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Middle Easta b s t r a c t
Background: Rotavirus (RV) is a major cause of gastroenteritis (GE) in infants and young children globally,
with rotavirus gastroenteritis (RVGE) causing dehydration due to diarrhea and frequently leading to hos-
pitalization. Epidemiological data on RVGE in Lebanon are lacking, therefore this study aims to collect
such baseline data.
Methods: We conducted multicenter, hospital-based surveillance across Lebanon to estimate the propor-
tion of diarrheal hospitalizations attributable to RV in children under 5 years of age. Medical history, GE
symptoms, treatment prior to hospitalization and demographics were obtained frommedical records and
parent/guardian interviews. The severity of GE episodes was determined using the 20-point Vesikari scale
(scoreP11 was considered severe). Stool samples were analyzed for RV using an enzyme immunoassay
and for strain prevalence using reverse transcriptase polymerase chain reaction.
Results: Between April 2007 and September 2008, a total of 534 subjects were enrolled, of whom 491
were included in the ﬁnal analysis. GE attributable to RV was 27.7% and nearly 75% of the RVGE cases
occurred in children under 2 years of age. No differences were observed between the severity of signs
and symptoms in RV positive and negative subjects. Hospitalization occurred mainly between Decem-
ber–March and lasted for a median of 3 days. Treatment primarily consisted of intravenous rehydration
and almost all subjects (96.1%) had recovered by the time of discharge. Prevalent circulating G and P
types were G4 (36.9%), G1WT (29.2%), P[8]WT (77.7%) and P[4] (17.7%); the most common circulating
RV strain was G4P[8]WT (36.9%).
Conclusion: RVGE hospitalizations are prevalent in children under 5 years of age in Lebanon. This baseline
data might be useful for decision makers when initiating measures, such as vaccination, to prevent the
disease.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
Rotavirus (RV) is a leading global cause of severe gastroenteritis
(GE) and dehydration in young children below the age of 5 years.
The World Health Organization (WHO) estimates that during
2008, around 453 000 (420 000–494 000) child deaths occurred
globally due to RV infection [1]. Furthermore, the Rotavirus Sur-
veillance Network (2001–08) predicted that worldwide 40% of
GE-associated hospitalization amongst children aged less than
5 years could be attributed to RV [2].
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come countries and represents a high healthcare burden, most
deaths due to RV occur in the developing world [3] where there is
poor access to medical care and underlying malnutrition. By the
time children are 5 years of age, most will have had at least one epi-
sode of RVGE [4]. Interventions that prevent diarrhea associated
with bacterial and parasitic agents, such as improvements in sanita-
tion and public hygiene, are, however, less effective against RV diar-
rhea, contributing to the public health challenge of RVGE [5].
In 2009, WHO recommended the inclusion of prophylactic RV
vaccination within national immunization programs to prevent in-
fant mortality and morbidity leading to hospitalizations due to RV
[6,7]. Currently, two oral vaccines (Rotarix™, GlaxoSmithKline Vac-
cines and Rotateq  Merck) are licensed in different parts of the
world and have shown good safety and efﬁcacy proﬁles in large
global studies [8–14]. These vaccines have also demonstrated efﬁ-
cacy against the globally circulating G and P types (G1, G2, G3, G4,
G9 and P[4], P[6], P[8]) which cause approximately 90% of the dis-
ease [15]. Pooled analyses show that vaccine efﬁcacy in high in-
come countries is higher than that in middle and low income
countries (85% vs. 51–61% respectively) [16]. Despite the lower
efﬁcacy in middle income settings, the introduction of these vac-
cines into national immunization programs has been associated
with a signiﬁcant decline in acute GE-related deaths and a dra-
matic reduction in hospitalization and outpatient visits in different
settings [17–19]. The beneﬁt of indirect protection after mass vac-
cination has also been suggested [20].
RV vaccination is currently not included in the national immuni-
zationprogram in Lebanon. There are reports on the epidemiologyof
RV in the Eastern Mediterranean Region [21], but epidemiological
data concerning RV disease burden in Lebanon are lacking. One sin-
gle-center, pilot study fromNorthLebanonhighlighted the role ofGE
viruses in causing severe acute GE requiring hospitalization
amongst youngchildren [22].However, for anypreventivemeasures
including vaccination to be considered, baseline epidemiological
data from across Lebanon would be required. We therefore con-
ducted a multicenter hospital-based surveillance study to deter-
mine the proportion of acute GE hospitalizations attributable to
RV in children under 5 years of age in Lebanon. We also estimated
the age and seasonal distribution of hospitalizations and the clinical
characteristics of RVGE in this population.Materials and methods
Study design
We conducted a hospital-based surveillance study in ﬁve large
urban, private hospitals in North, Central and South Lebanon, be-
tween April 2007 and September 2008. The Nini Hospital in Trip-
oli; American University of Beirut Medical Centre, Hôtel-Dieu de
France and Makassed General Hospital in Beirut; and Hammoud
Hospital University Medical Centre in Saida are tertiary care cen-
ters with well established pediatric departments.
Lebanon is a developing country, classiﬁed according to the
World Bank Income Group as an upper middle income country.
WHO estimates the population under-ﬁve years of age to be
around 328,000 [23].Study population
Children under 5 years of age who were admitted to the partic-
ipating hospitals with a diagnosis of acute GE were eligible. GE was
deﬁned as occurrence of diarrhea with or without vomiting and
acute GE was deﬁned as diarrhea of 614 days duration. Subjects
were excluded if the admitting diagnosis at the site did not includeGE, or if the subject developed GE longer than 12 hours following
hospitalization (possible nosocomial infection). Enrolment was
sequential and children hospitalized more than once were enrolled
as new subjects on each occasion.
Medical history was collected from parent/guardian interviews
and from medical charts. It included information about demo-
graphics, GE symptoms, severity, and treatment prior and during
hospitalization and outcome. GE episode severity was determined
using the 20-point Vesikari scale, where a score of P11 was con-
sidered as severe [24].
Procedure
Stool samples collected during the acute episodes of GE were
stored at a temperature between 2 C and 8 C for 24 h and then
at temperatures from 20 to 70 C. All samples were tested
on-site for the presence of RV using an enzyme immunoassay
(Premier™ Rotaclone; Meridian Bioscience, Europe). RV positive
samples were additionally genotyped to identify G and P types
using reverse transcriptase polymerase chain reaction (RT-PCR)
of the VP7 and VP4 genes followed by reverse hybridization at
the DDL Diagnostic Laboratory (Rijswijk, The Netherlands) [25].
The surveillance activities followed Good Clinical Practice and
the principles outlined in the Declaration of Helsinki. Ethical com-
mittee approval was obtained from the institutional review boards
of each study center. All parents/legal guardians of the subjects
gave written informed consent before the study start.
Statistical analyses
The ﬁnal analysis was performed on all subjects whomet the eli-
gibility criteria. Summary statistics for demographic characteristics
and percentages for the categorical data were computed. To esti-
mate the proportion of diarrheal hospitalizations attributable to
RV in children aged less than 5 years, the number of children with
RVGEwas divided by the number of children with GE and the result
multiplied by 100 (to express as percentage). Chi square test and
Fischer’s exact test were performed as an exploratory analysis to
compare symptoms and delineate differences in the proportion be-
tween RV positive and negative subjects. All statistical analyses
were descriptive and performed using SAS version 9.2. The 95% con-
ﬁdence intervals (CIs) were calculated using ProcStatXact.
Results
Demographic characteristics
A total of 534 subjects were enrolled in ﬁve urban hospitals
across Lebanon; 491 of these were included in the ﬁnal analysis
(a total of 43 subjects were excluded: 10 subjects did not satisfy
the inclusion/exclusion criteria after the stool sample collection,
2 subjects did not have the same dates for admission/interview
and informed consent, 15 subjects violated the protocol, 15 sub-
jects did not have laboratory results, and 1 subject had late stool
sample collection). Five out of the 491 subjects did not have any
diarrhea but had vomiting and were enrolled according to the local
practice (wherein subjects with diarrhea and/or vomiting were
considered as GE cases). Overall, the median age of the subjects en-
rolled was 12 months (0–59 months), the mean weight (standard
deviation [SD]) was 10.4 (3.4) kg and 44.4% of the subjects were fe-
male. The demographic characteristics were similar in both RV po-
sitive and RV negative groups. The number of subjects per
participating hospital was higher for Makassed General Hospital
(158) and Nini Hospital (155) but lower for the Hammoud Hospital
University Medical Centre (84), American University of Beirut
Medical Centre (56) and Hôtel-Dieu de France (38).
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Stool samples were tested for 99.2% (487/491) of the subjects;
27.9% (136/487) were RV positive and 72.1% (351/487) were RV
negative. For the remaining four subjects, stool samples were not
collected for testing and therefore RV status was denoted as un-
known. The overall proportion of GE hospitalizations among chil-
dren under 5 years of age attributable to RV was 27.7% (95% CI:
23.8–31.9%). Proportions of GE hospitalizations diagnosed with
RVGE by center (A) and by age (B) are summarized in (Fig. 1). Mak-
assed General Hospital (Beirut) recorded the highest number of
cases of RVGE and GE hospitalization (Fig. 1A) and the majority
(75%) of RVGE hospitalized children were under 2 years of age
(Fig. 1B). The number of hospitalizations peaked between Decem-
ber 2007 and March 2008 (Fig. 2). The highest numbers of GE cases
were reported in December and January, which coincided with the
months during which RV cases were more frequent.Clinical characteristics of RVGE hospitalizations
Most subjects with GE diagnoses experienced diarrhea (486
[99%]) and vomiting (400 [81.5%]) before hospitalization; the
majority (414 [84.3%]) continued having diarrhea during their hos-




















Fig. 1. Proportions of GE hospitalizations diagnosed within Table 1. Before hospitalization, severe GE was observed in 79.4%
RV positive and 76.1% RV negative subjects, whilst during hospital-
ization, severe GE occurred in 13.2% and 16.8% of subjects,
respectively.
The overall median length (SD) of hospitalization was 3 (±2)
days, with no differences observed by RV status. In-patient treat-
ment consisted primarily of intravenous rehydration which was
administered to all RV positive and to 96.3% RV negative subjects
(P = 0.024). More RV negative subjects were treated with antibiot-
ics compared with RV positive subjects (43.0% vs. 23.5%,
P = <0.0001). At the time of discharge, 96.1% (472/491) of all sub-
jects had recovered. Among RV positive subjects, 94.9% (129/136)
subjects recovered and 5.1% (7/136) had ongoing GE. Among RV
negative subjects, 96.6% (339/351) subjects recovered, 3.1% (11/
351) had ongoing GE, and one subject (who had GE and osteomy-
elitis) was transferred to another hospital.Prevalence of RV types
Stool samples from 130/136 RV positive subjects were RV typed
(for 6 subjects, the quantity of sample was insufﬁcient to perform
typing). Prevalent G-types were G4 (36.9%) and G1WT (29.2%). The





























































Number of  RV-positive hospitalizations (N=136)
Number of  RV-negative hospitalizations  (N=351)
Number of  RV-unknown hospitalizations  (N=4)
% of  GE hospitalized due to RV
Fig. 2. Seasonal distribution of RVGE and GE hospitalizations, N = 491
Table 1
Symptoms and treatment of children hospitalized for acute GE by Rotavirus (RV) status and overall
% RV-positive subjects (N = 136) % RV-negative subjects (N = 351) Overall subjects (N = 491)
Before hospitalization
Symptoms Diarrhea 98.5 99.1 99
Vomiting 87.5 79.2 81.5
Fever 81.6 86.3 84.9
Duration of diarrhea (in days) 0 days 0 1.1 0.8
1–4 days 91.7 85.1 87
5 days 3 5.7 4.9
P6 days 5.3 8 7.2
Severity of GE (Vesikari scale) Mild (<7) 0.7 1.4 1.2
Moderate (7–10) 19.9 22.5 21.8
Severe (P11) 79.4 76.1 77
During hospitalization
Severity of GE (Vesikari scale) Mild (<7) 44.9 41 41.8
Moderate (7–10) 41.9 42.2 42.4
Severe (P11) 13.2 16.8 15.9
Treatment Oral rehydration 65.4 61.5 62.9
Intravenous rehydration 100.0a 96.3a 97.4
Antibiotics 23.5b 43.0b 37.5
a P = 0.0234.
b P = <0.0001.
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tion type (Fig. 3).
Discussion
Our hospital-based surveillance provides prevalence data on
morbidity and hospitalization due to RVGE in ﬁve pediatric referral
hospitals across Lebanon; over 500 subjects were enrolled with
acute GE and tested for RV during the 2007–08 season. We found
that 27.7% of the admissions for acute GE in children under 5 years
of age were attributable to RV infection. Furthermore, nearly 75% of
the RVGE cases occurred in children under 2 years of age. All severe
cases were treated with intravenous rehydration therapy. To our
knowledge, this is the ﬁrst study to collect such representative
data.
WHO estimated the probability of deaths by the age of 5 years
in Lebanon as 31 per 1000 live births for 2006. Of these, 1% ofdeaths were due to diarrhea [26]. Further, WHO data indicate that
in 2008, fewer than 10 (95% CI, 0–10) deaths in this age group were
due to RV; thereby giving a RV mortality rate of 3 per 100,000 pop-
ulation in under 5 year olds [27]. Studies from other countries in
the Middle East estimate the overall annual proportion of RVGE
among reported episodes of GE in young children to range between
33–53% [22,28–30], although lower rates (16–23%) have been re-
ported from Saudi Arabia, and Egypt [31–33]. Our study result of
27.7% falls in the range estimated by these neighboring countries.
However, as these studies were carried out in settings with differ-
ent populations and using different laboratory settings, compara-
bility is limited.
Over the year-long surveillance period, the majority of RVGE
cases were observed between December and March, which is con-
sistent with the reported RVGE seasonal trend of a peak during the
dry cold season [30,34]. In our study, the most prevalent RV types
were G1, G4, P[4] and P[8] with G4P[8]WT being the most common
Fig. 3. Distribution of rotavirus strains, N = 130
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gion showing G1P[8] to be the most prevalent combination in the
Middle Eastern and North African pediatric populations [30]. An
exploratory analysis was carried out to delineate the differences
between RV positive and negative subjects. Statistically signiﬁcant
differences were found only with respect to antibiotic treatment
and intravenous rehydration therapy. However, these differences
should be interpreted with caution as there may be differences
in clinical practice among centers regarding antibiotic use. More-
over, confounding factors including socio-economic aspects may
also play a role, but were not considered for our analysis.
The results of our study need to be interpreted in the context of
some limitations. We initially planned to compute incidence data
of RVGE in Lebanon, but incidence could not be calculated due to
uncertainty about the exact size of the population in the catchment
areas. Our study was also designed to assess only hospitalized
cases with acute GE in urban cities; therefore data from children
who were managed at home were not collected. Additionally, as
data were collected for only one year, it is difﬁcult to draw conclu-
sions about the seasonality of RVGE, and indicates the need for
longer term studies in the future. Despite these limitations, the
main strengths of our multicenter pediatric study were in under-
taking systemic surveillance using WHO indications and using a
validated laboratory for strain identiﬁcation and G and P typing.
The observations of our study emphasize the role of RV as a cause
of acute GE hospitalizations in children under 5 years in Lebanon.
Our study highlights the need for preventive measures against
RVGE in Lebanon. Currently, the acute dehydration caused by RVGE
is managed by ﬂuid and electrolyte replacement; there is no avail-
able anti-viral therapy [35]. Vaccination, however, represents an
effective public health intervention for RVGE disease and since
the 2009 WHO recommendation countries have started adopting
RV vaccines in their routine childhood vaccine programs [36,37].
Bahrain (2008), Qatar (2009) and more recently Iraq and Yemen
(2012) in the Middle Eastern Region have introduced RV vaccina-
tion in their national immunization plans [38]. Future studies will
need to be conducted to follow up the impact of rotavirus vaccine
introduction in these countries. Data from studies in real world
settings globally have shown substantial public health impact of
RV vaccination in reducing the disease burden and hospitalizations
due to RVGE [39,17].
A prophylactic vaccination strategy might reduce the disease
burden and the associated economic costs of RVGE. Establishing
a surveillance system in sentinel hospitals to monitor the circulat-
ing RV strains will help to determine the emergence of new geno-types and give further direction to optimal and effective
prevention strategies. Our data provide the prevalence of morbid-
ity and hospitalizations due to RVGE and highlight the need for
strategic measures against RV in Lebanon.
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